Table 3

Timing of data collection during the study

ScreeningInclusionM6 (M5–M7)M8–M10M12 (M11–M13)
Eligibility assessmentX    
Information and consent X   
Inclusion and non-inclusion criteria X   
Clinical examination     
 SpO2, mMRC  X X*
Paraclinical examinations     
 6MWT  X X*
 PFT: spirometry, plethysmography and DLCO  X X†
 Chest CT  X X‡
Olfaction and taste questionnaire and visual analogue scale XX  
Neuromuscular assessment  X X
 ADL Katz  X X
Cognitive state: MoCA  X X
 Self-reported questionnaires: HADS, IES-R, SF-36, VSRQ  X X
Nutritional status: weight, food intake XX  
Data collection     
Baseline characteristics X   
 Sociodemographic characteristics X   
 Comorbidities X   
 Life habits X   
 Healthcare utilisation X   
Data related to ICU stay X   
 SOFA, SAPS II X   
 Life support therapy X   
 Management X   
 ARDS X   
Rehabilitation after ICU discharge  X X
Vital status  X X
Semistructured interview   X 

  • *For patients with desaturation at effort, or walked distance <90% of the theoretical value on 6MWT at 6 months

  • †For patients with at least one of the following: FVC <80% of the theoretical value, FEV1 <80% of the theoretical value, DLCO <80% at 6 months

  • ‡For patients with pulmonary involvement (fibrosis-like lesions, reticular and/or residual ground glass opacities, mosaic pattern) on chest CT at 6 months

  • ADL, activities of daily living; ARDS, acute respiratory distress syndrome; DLCO, diffusion capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HADS, Hospital Anxiety and Depression Scale; ICU, intensive care unit; IES-R, Impact of Event Scale Revised; mMRC, modified Medical Research Council; MoCA, Montreal Cognitive Assessment; 6MWT, 6 min walk test; PFT, pulmonary function test; SAPS II, Simplified Acute Physiological Score; SF-36, Short Form Health Survey modified 36; SOFA, Sequential Organ Failure Assessment; SpO2, peripheral capillary oxygen saturation; VSRQ, Visual Simplified Respiratory Questionnaire.